Clarity Signs Manufacturing Supply Agreement for Copper-64 With Theragenics

Why It Matters

Securing high‑volume Cu‑64 production removes a key logistical barrier for 64Cu‑SAR‑bisPSMA, positioning Clarity to meet nationwide demand and accelerate commercialization in the fast‑growing prostate‑cancer imaging market.

Key Takeaways

• Theragenics can produce 100 Ci copper‑64 daily per cyclotron
• 64Cu‑SAR‑bisPSMA offers 48‑hour shelf life, improving logistics
• Clarity now has three U.S. copper‑64 manufacturing partners
• Longer half‑life reduces waste and costs versus Ga‑68
• Phase III trials nearing completion boost commercial launch prospects

Pulse Analysis

Copper‑64’s 12.7‑hour half‑life gives it a distinct advantage over traditional PET isotopes such as gallium‑68 and fluorine‑18, which decay in under two hours. The extended decay window translates into a 48‑hour shelf life for 64Cu‑SAR‑bisPSMA, enabling centralized production, broader geographic distribution, and more flexible scheduling for prostate‑specific membrane antigen (PSMA) imaging. This technical edge addresses a long‑standing bottleneck in radiodiagnostics, where short‑lived isotopes drive high costs, waste, and limited access.

The new supply agreement with Theragenics adds a high‑capacity, U.S.-based source to Clarity’s existing network that includes SpectronRx and Nusano. Theragenics’ 14‑cyclotron fleet can deliver roughly 2,000 patient doses per day per cyclotron, ensuring a robust pipeline for the anticipated commercial launch of 64Cu‑SAR‑bisPSMA. By anchoring production near Atlanta—a major transport hub—Clarity reduces logistical complexity and positions itself to meet demand across multiple oncology indications once the Phase III AMPLIFY and CLARIFY trials secure FDA approval.

Beyond Clarity, the partnership signals a shift in the radiopharmaceutical industry toward scalable, profit‑driven isotope manufacturing. The ability to produce copper‑64 at commercial scale could lower per‑dose costs, diminish radioactive waste, and open new markets for high‑resolution PET imaging. As prostate‑cancer diagnostics grow and Fast Track Designations accumulate, investors and clinicians alike will watch how this supply chain expansion influences pricing, reimbursement, and the broader adoption of next‑generation radiometals.